Breath sniffing may reveal early clues to cystic fibrosis drug success

NCT ID NCT05726994

First seen Jul 01, 2026 · Last updated Jul 01, 2026

Summary

This study explores whether analyzing the chemicals in exhaled breath can detect early changes in children with cystic fibrosis who start taking a medication called Kaftrio. Researchers will collect breath samples from 50 children under 12 before and after they begin treatment, looking for shifts in volatile organic compounds (VOCs) that might signal the drug is working. The goal is to develop a non-invasive way to monitor treatment response without needles or scans.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

exhaled breath collection

What this could lead to

If successful, this could lead to a simple breath test to monitor how well CFTR modulators are working in young children with cystic fibrosis.

What could go wrong

This is a small pilot study, so results may not apply broadly. The breath profile changes may be too subtle or variable to be clinically useful.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CYSTIC FIBROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cystic fibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Hôpital Necker - Enfants malades

    Paris, Île-de-France Region, 75015, France